The analysis of antibodies in human serum is an established technique in the laboratory diagnosis of infectious as well as autoimmune diseases. The multitude of antibody reactions towards pathogens and likewise the antibody profile in autoimmune diseases does contain a wealth of proteomic (antibody) data that may constitute valuable diagnostic information with relevance for the patient's prognosis and response to therapy. Hence the use of antibodies as diagnostic biomarkers may be one of the most promising strategies to identify patient subgroups. The presence or absence of antibodies directed against specific epitopes could represent a serologic biomarker that is able to predict the severity of a disease and assist in medical decision making. In addition, parallel detection of many different antibodies in a serum sample would be of great value in many areas of basic immunological research. Peptide arrays displaying biologically active small synthetic peptides in either low, medium or high-density formats represent an attractive technology to probe complex serum samples for the presence of such antibody analytes. Holding the unique capacity to break down the heterogeneous immunologic response into monoclonal antibody specificities and to differentiate subtle changes in antibody abundance and specificity, the peptide array technology by far extends the diagnostic potential of any conventional serologic assay. Together with an unrivalled parallelity, peptide (micro)array analysis opens new perspectives for the novel use of antibodies as diagnostic biomarkers and provides unique access to a more differentiated serological diagnosis. This review recapitulates the development of the peptide array technology with a focus on recent advances and current state of the art platforms for antibody diagnostics. Latest applications of peptide arrays for the serologic diagnosis of infectious diseases, autoimmunity and allergy are discussed, and conclusions for future developments and implications are drawn.
multipin technique (Geysen et al., 1984; Geysen et al., 1985) . The group adopted SPPS to display surface bound peptides on polyethylene rods with the format and spacing of a microtiter plate. For instance, they synthesized 208 overlapping hexapeptides covering the entire 213 amino acid sequence of the foot-and-mouth disease virus coat protein and tested the pin-coupled peptides for antigenicity in an ELISA format with six different rabbit antisera. With this approach it was not only possible to characterize an immunodominant epitope at the resolution of single amino acids, but their work also highlighted the variability in the individual immune responses to an identical antigen (Geysen et al., 1984) . In contrast to this parallel synthesis concept, other approaches to generate highly diverse libraries of peptides during those years focused on split and mix synthesis methods ('tea bag' synthesis (Houghten, 1985) , 'one bead one peptide' (Lam et al., 1991) ). These strategies, however, yielded (random) peptide libraries for solution phase assay. The identity of an individual (hit) peptide sequence had to be determined afterwards, which precluded its wider use in bioassays.
Shortly thereafter, peptide arrays were taken to the next level when Ronald Frank invented the SPOT synthesis (Frank and Döring, 1988; Frank, 1992; Frank, 2002) . This technology distinguishes itself from previous SPPS methods in the way that conventional solid phase chemistry is used for in situ synthesis of peptides on cellulose membranes. Simplicity and robustness of the SPOT method soon led from manual synthesis into automated systems, and the close relation of SPOT membrane assays with procedures and reporter systems well-known from conventional bioassays, e. g. western blots, furthered a broad acceptance in research laboratories, even those not experienced in peptide chemistry. In accordance with the focus of this review, most of the research activities incorporating SPOT synthesis were aimed at systematic studies on molecular recognition events in the immune system based on synthetic peptides (Frank, 2002) , including generic strategies (Kramer et al., 1995; Reineke et al., 2002) as well as epitope and paratope mapping based on available protein sequence information (Frank and Overwin, 1996; Monnet et al., 1999; Hilpert et al., 2001; Cohen et al., 2001; Laune et al., 2002) . The numerous applications of the SPOT synthesis have been surveyed in several reviews (e. g. Reineke et al., 1999; Reineke et al., 2001; Frank, 2002) . Despite the limited density of the resulting peptide arrays of 9-25 spots cm -2 during a current trend of micrometer-scaled biochip formats, the method has hardly lost its attractiveness, not at least because the cost per peptide is less than 1% of peptides synthesized conventionally on resin (Hilpert et al., 2007) . Rececently, Beyer et al. have presented a particlebased approach for a modified Merrifield synthesis of peptide microarrays (Beyer et al., 2007) capable of drastically increasing spot density to 40.000 per cm 2 . Utilizing activated amino acid monomer particles directed by electric field patterns of individual pixel electrodes they demonstrated the technical feasibility of a coupling process initiated by melting the particles.
In 1991, Fodor and co-workers presented their concept of parallel photolithographic, spatially addressable in situ solid phase synthesis on glass slides (Fodor et al., 1991) . In the following genomics era, it fell broadly into oblivion that it was in fact a peptide chip that hallmarks the emergence of the microarray technology. Fodor introduced photolabile Nprotecting groups and photomasks to generate in repetitive cycles of light-directed deprotection and coupling a combinatorial array of 1024 synthetic peptides on 1.6 cm 2 . The peptide microarray was successfully used for the identification of peptidic antigens, however, the production of building blocks with photolabile protecting groups was only shown for eight amino acids. It was the requirement for large quantities of photomasks and special building blocks that led to further advances in photolithographic peptide synthesis. The Gao group used conventional monomers with acid-labile Boc-protection group and a photogenerated acid for the maskless production of peptide microarrays (LeProust et al., 2000; Pellois et al., 2000 , Pellois et al. 2002 , Gao et al., 2003 . The high-resolution patterning (2000-4000 peptides on 1.5 cm 2 ) was accomplished with digital photolithography, a process in which a computer generated virtual photomask controls the site-specifically addressable illumination of the chip surface by means of a digital micromirror array.
The introduction of robotic microdispensers (Schena et al., 1995) led to a general increase in the application spectrum of peptide arrays in low, medium and high density formats. The instruments are used to print (or "spot") solutions of pre-synthesized peptides onto suitable microarray substrates, i. e. surfaces with either chemical or physical peptide binding capacity. Modern manufacturing methods include contact printing technology with different types of microspotting pins assembled in printheads (Schena, 2003) , and noncontact printing which usually involves piezoelectric inkjet technology (Schena, 2003) . The most significant advantage of microarray manufacturing by spotting technology, particularly for diagnostic purposes, is the possibility to implement peptide purification and quality control into the manufacturing process, and to modularly combine sets of peptides with high redundancy and utmost flexibility. Hence, all the clinical applications of peptide microarrays discussed here have been manufactured by printing technology (Fig. 1) .
PEPTIDE DISPLAY ON MICROARRAY SUBSTRATES
The functional surface display of the antigen is a prerequisite for in vitro antibody diagnosis. In the case of peptide arrays, the reduction of complex protein antigens to short peptides will almost inevitably be associated with a drastic change in topology and conformation of the native ligand. Short peptide sequences are rarely capable of intramolecular interaction and usually do appear in a linear rather than a three-dimensional structure. Synthetic peptides are therefore essentially restricted to the mimicking of continuous epitopes, and their use is limited when complex three-dimensional structures are necessary for a given biological function. The requirements for surface immobilization of biochemically active peptides differ considerably from those of whole proteins. The group of Frank Bier addressed this issue in a systematic study on the functional surface display of peptides for microarray based antibody diagnostics (Andresen et al., 2006b) . In this study, effects of spacer incorporation and peptide surface orientation on antibody capture were analyzed using a system of peptide determinants deduced from central and terminal parts of viral and phage proteins. Although these findings unveiled significant differences in the individual mechanisms of peptide-antibody interactions on the surface, it was possible to attribute the dominating effect to the accessibility of key epitope residues in the ligand rather than an influence of the peptide immobilization direction, i. e. a free amino or carboxy terminus.
Low molecular weight peptides are extremely heterogeneous in their physico-chemical properties. For this reason, a uniform unspecific immobilization of peptide probes by simple physisorption is not feasible beneath a critical peptide length. Yet, there is at least one study utilizing unspecific adsorption on polymer-modified glass as a means of peptide fixation on the chip (Chiari et al., 2005) . Usui and coworkers have proposed a system of drying peptides on a microchamber array, which then is used to quantify interactions with a fluorescently labelled protein in solution (Usui et al., 2006) . The use of conventional bioconjugation protocols that unspecifically target nucleophiles in biomolecules, e.g. amines, sulfhydryls and hydroxyls (Hermanson, 1996) , often impairs a peptide's ability to be recognized by other molecules. A high proportion of these functional groups may contribute to the antibody interaction, and their chemical modification may result in a complete loss of the peptide's biochemical function. The coupling of peptides carrying a terminal cystein via SMCC (Beyer et al., 2006) onto surfaces is only feasible when these peptides bear no other cysteins in their sequence. The selective, that is to say site-specific immobilization of multivalent peptides is demanding: the absence of moieties with an intrinsic reactivity orthogonal to other functional groups in biomolecules necessitates modifying the peptides with a suitable linker function during synthesis that later selectively reacts with a complementary function on the chip surface. Since the mid-1990s, a variety of chemoselective ligation reactions have been developed to covalently link unprotected peptide segments together in order to assemble artificial proteins from synthetic fragments (Schnolzer and Kent, 1992; Dawson et al., 1994; Tam et al., 1995; Liu et al., 1996; Tam et al., 2001) or to specifically address and manipulate biomolecules in complex cellular environments (Mahal et al., 1997; Lemieux and Bertozzi, 1998; Saxon and Bertozzi, 2000) . Several versions of these reaction principles have later been adopted for the covalent peptide immobilization on solid phase: different embodiments of semicarbazone and hydrazone chemistry (Melnyk et al., 2002; Duburq et al., 2004; Lee and Shin, 2005; Coffinier et al., 2007; Andresen et al., 2008) , oxime bond or thiazolidine ring ligation (Falsey et al., 2001; Salisbury et al., 2002; Shigaki et al., 2007) , native chemical ligation (Lesaicherre et al., 2002; Uttamchandani et al., 2004) , staudinger ligation (Soellner et al., 2003; Köhn et al., 2003) and copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides (Tornøe et al., 2002; Lin et al., 2006) as well as a diels-alder reaction (Houseman et al., 2002 ). Another, non-covalent immobilization strategy takes advantage of the well-characterized biotin-avidin affinity capture (Lesaicherre et al., 2002; Andresen et al., 2006a; Andresen et al., 2006b; Andresen et al., 2006c) (Fig. 2) .
In sum, the site-specific immobilization of peptide probes along with a high local probe density and unrestrained probe accessibility results in the formation of multivalent antibody:peptide complexes and the frequent rebinding of antibodies after complex dissociation. The beneficial outcome of this instance is a high apparent affinity of serum antibodies that correlates with a low detection limit of the immunoassay.
SEROLOGICAL ASSAY FORMATS AND READ-OUT ON PEPTIDE ARRAY PLATFORMS
The predominant serological assay types used with peptide arrays are rather conventional, with sandwich assays involving labelled secondary antibodies being most widely used. The arrays are directly incubated with diluted serum, followed by a washing routine and labelling of immunocomplexes with a preparation of secondary antibodies carrying a suitable reporter function. Like in DNA microarray analysis, the use of fluorochrome labels prevails, which allows the detection of captured serum antibodies by means of customdesigned microarray scanners or chip readers and image analysis software (Melnyk et al., 2002 Andresen et al., 2008) . Enzyme labels catalyzing chemiluminescence or precipitate formation and radioisotope labels, both commonly used in solid phase ELISA and western blot procedures, have been primarily used to develop membrane-based arrays of low spot density (Hilpert et al., 2001; Reineke et al., 2002; Laune et al., 2002; Frank, 2002) . The benefit of these techniques is that conventional desk-top flatbed scanners can be used for array imaging, making costly investments in specialised in- strumentation negligible. Neither enzymatic nor radiometric detection, however, provides sufficient spatial resolution to be applicable to high-density microarrays (Seong and Choi, 2003) . The use of gold nanoparticles for colorimetric detection may be a reasonable alternative, since it is compatible with both a high spatial resolution and inexpensive detection instruments (Taton et al., 2000; Han et al., 2003) . Alexandre and colleagues presented a microarray-compatible method, in which the colorimetric signal is generated by photographic silver precipitation onto gold nanoparticles (Alexandre et al., 2001) . The amplification power of the autocatalytic metallic deposition process resulted in a detection limit of 0.1 fmol of the target molecule, which was equivalent to the use of a Cy-3 fluorescence label.
Label-free assay technologies with high-throughput, highcontent capabilities are an emerging technology (Boozer et al., 2006) . The direct, label-free detection of antibody binding in serological diagnosis has some principal advantages over the conventional formats that involve end-point determination of fluorescent, enzymatic, radiometric or other reporter functions. They allow real-time monitoring of the biomolecular interaction and avoid elaborate and timeconsuming multi-step procedures. Hence, the assay gets cheaper and considerably faster, the whole procedure is usually a matter of minutes. In addition, kinetic and affinity data can be gained. Kröger et al. were the first to report the adaptation of a label-free technology to high throughput peptideprotein interaction monitoring (Kröger et al., 2002) . They used reflectometric interference spectroscopy (RifS) and an array of 21 pentapeptides to map the epitope of an antibody against tissue transglutaminase in a single experiment. Another label-free HTS/HCS technology is provided by the recent development of surface plasmon resonance imaging Fig. (2) . Different embodiments of covalent and non-covalent site-specific immobilization of synthetic peptide probes on microarray substrates. A: glyoxylyl linker and semicarbazide surface (Melnyk et al., 2002) , B: hydrazide linker and epoxide surface (Lee and Shin, 2005) , C: hydrazine linker and aldehyde surface (Andresen et al., 2008) , D: oxy-amine linker and glyoxylyl surface (Falsey et al., 2001; Salisbury et al., 2002) , E: N-terminal cystein linker and glyoxylyl surface (Falsey et al., 2001) , F: N-terminal cystein linker and thioester surface (Lesaicherre et al., 2002) , G: azide linker and phosphinothioester surface (Soellner et al., 2003) , H: terminal alkyne linker and azide surface (Tornøe et al., 2002) , I: cyclopentadiene linker benzoquinone surface (Houseman et al., 2002) J: biotin linker and streptavidin surface (Lesaicherre et al., 2002) , K: two-step procedure with solution-phase coupling of biotinylated peptides to hydrazide-modified streptavidin, followed by the chemoselective reaction of the hydrazide linkers with an aldehyde surface (Andresen et al., 2006c) .
(SPRi) which overcomes the limited throughput of traditional SPR sensors. Wegner et al. established a SPRi platform with an array of FLAG peptide variants to simultaneously interrogate the binding characteristics of a monoclonal anti-FLAG antibody to the different peptides and to obtain kinetic data (Wegner et al., 2002) . Baggio and co-workers used imaging SPR in a 12 15 SpotMatrix to generate affinity traces for the binding of a monoclonal antibody to peptide mutants of a continuous epitope within the human class II MHC protein HLA-DR1 (Baggio et al., 2005) . The comparative evaluation of the kinetic details of antibody binding showed that both improvement and reduction of the interaction were due to differences in the dissociation rate and provided evidence for a structure-dependent binding mechanism. Recently, Cherif et al. combined the advantages of peptide arrays and label free detection by SPR imaging for the serological multiparameter diagnosis (Cherif et al., 2006) . They displayed a panel of 12 different peptides derived from structural and non-structural proteins of the hepatitis C virus and used SPRi to sketch the antibody response of HCV-seropositive and seronegative patients against these peptides. Their findings highlighted differences in specificity and strength of the anti-HCV immune reaction within a group of eleven patients. A future aspect of this technology may be to extract kinetic information from such immune profiles in order to provide valuable diagnostic information beyond antibody abundance and specificity.
PEPTIDE ARRAYS IN ANTIBODY CHARACTERI-ZATION AND SERUM ANALYSIS
The diversity of the antigen-specific humoral immune response reflects the interaction of the immune system with pathogens, allergens and autoantigens. Diversification, along with affinity maturation and class switch recombination, is the result of immune progression -a process that is specifically regulated and may provide insight into the host immune response. A number of clinical correlations have been made among antibody diversity and clinical allergy, antiinfective immunity and clinical autoimmunity. Consequently, not only the mere identification of a pathogen but also the detailed qualitative and quantitative analysis of the resulting humoral immune response can be valuable in clinical decision-making.
Antibodies that recognize a linear stretch of a polypeptide chain have been shown to bind peptides mimicking these amino acid sequences. The size of such an antibody binding site, a continuous epitope, was found to be usually between 5 and 8 amino acids in length. Consequently, the length of the peptides used in different assays typically varies between 8 and 13 amino acids. Shreffler and coworkers, however, reported the identification of some allergen epitopes recognized by IgE and IgG 4 antibodies, where only 15-mer or 20-mer peptides showed significant antibody binding (Shreffler et al., 2005) , but this can also be the result of either an improved accessibility of the key amino acids within the longer sequences or due to the preformation of secondary structures necessary for the antibody binding rather than the length of the epitope itself.
Therefore, short synthetic peptides can be used as probes to specifically detect antibodies from complex biological fluids. The ease and speed of production makes peptides ideal probes and peptide microarrays an efficient screening platform for the determination of the antibody spectrum in human serum, liquor, saliva and other body fluids (Fig. 4) .
Very early during their development, peptide arrays had been utilized for the mapping of antibody binding sites. This has been carried out for a vast variety of monoclonal antibodies. SPOT membranes and other array formats have been used to characterize the antibody repertoire in response to immunization in animals. Reineke and colleagues demonstrated the enormous potential of peptide arrays for the identification of antibody reactivities by using a relatively small library of 5520 random peptides to identify epitopes of four monoclonal antibodies (Reineke et al., 2002) . Substitutional analyses of initially selected candidate peptides allowed them to find ligands with low micromolar or nanomolar affinities. The authors were able not only to retrieve known epitope sequences from that library but also unrelated mimotopes. Earlier, Halimi and coworkers had shown, that an ELISA using conventionally synthesized peptides and a SPOT peptide array agreed in their results when applied to epitope analysis of rabbit and human sera (Halimi et al., 1996) . Over the past years, peptide microarray technology has been adopted and proven useful not only for epitope mapping of monoclonal antibodies but also for the detailed analysis of antibody profiles in human serology.
AUTOEPITOPE MAPPING
Since the early 1990s, a number of systematic studies in autoimmune diseases had shown that in patient sera, antibodies reacting with peptides of a self-protein but not with the protein itself can be found (for review, see (Fournel and Muller, 2003) ). Other antibody subpopulations reacting with both protein and peptides co-exist with the former ones. This phenomenon is often discussed in the context of either differential sensitivities of the assays or reduced exposure of the epitope in a full-length protein under assay conditions. Many ELISA formats do not involve denaturing conditions for protein preparations. Likewise, certain postranslational modifications, e.g. deimination and phosphorylation of amino acids side chains may not be introduced by recombinant systems for protein antigen production.
The serological analysis of patients with autoimmune disorders with peptide arrays revealed dominant epitopes in protein antigens and provided evidence for antibody specificities that are associated with specific disease or disease subsets (reviewed in (Fournel and Muller, 2003) ). The pin technology introduced by Geysen (Geysen et al., 1984) was used in several of these studies to map various antigens with autoantibodies, for instance such associated with systemic lupus erythematosus and Sjögren's syndrome including the sequences of Sm D1 and B/B' proteins (Williams et al., 1990; James and Harley, 1992; James et al., 1994; McClain et al., 2002) , Ro60 (Scofield and Harley, 1991) and La/SSB (Tzioufas et al., 1997) , as well as proteinase-3 (Wegener's granulomatosis) (Williams et al., 1994) . Likewise, the SPOT method was utilized to create peptide libraries for epitope mapping of Sm D1 (Riemekasten et al., 1998) , SSB/La (Haaheim et al., 1996) , collagen IV (Goodpasture's disease) (Levy et al., 1997) and proteinase-3 (Griffith et al., 2001) .
Several of these studies demonstrated the great potential of peptide-based diagnostic tests to serologically discriminate patients with certain autoimmune disorder from those with other rheumatic or inflammatory diseases. However, the expansion and maturation of the humoral immune response known as epitope spreading observed for both systemic and organ-specific autoimmune diseases might impair the sensitivity of diagnostic test based on single peptides, i. e. single antibody biomarkers only (James and Harley, 1998; Monneaux and Muller, 2002) . Fournel and Muller therefore proposed to implement cocktails of peptides to cover a majority of individuals and thereby optimize the sensitivity of diagnostic assays (Fournel and Muller, 2003) . In this regard, (micro-) arrays are ideal platforms not only to detect relevant antibodies but also distinguish fine-specificities which might be symptomatic for pathogenesis or prognosis, since there are instances where the final clinical manifestation of the autoimmune disease also depends on the relationship of the antibodies' relative concentrations.
One of the first applications of peptide microarrays for antibody profiling of clinical samples was the study of Robinson et al. on the multiplex characterization of autoantibody responses (Robinson et al., 2002) . 196 distinct putative autoantigens of various nature and origin were spotted on glass slides, including purified or recombinant proteins and nucleic acids. In addition to these antigens, the authors also used 154 overlapping and immunodominant synthetic peptides representing autoantigens like snRPN and Sm proteins as well as PARP and histones. The results demonstrated that subsets of linear peptides were recognized by antibodies from patients with autoimmune diseases and further enabled the epitope mapping of autoantibody responses. The potential clinical impact of such analyses was highlighted by a more recent paper from the same group. Proteomic analysis of autoantibody reactivities using a 1536-feature microarray of 225 peptides and proteins enabled the stratification of patients with early rheumatoid arthritis into clinically relevant disease subsets. Citrullinated epitopes represented by synthetic peptides on the array were found to be present in a group of patients with features predictive of severe disease (Hueber et al., 2005) .
Our own group set up a peptide microarray displaying the entire sequence of the autoantigenic human thyrotropin receptor in overlapping synthetic 15-mer peptides (Andresen et al., 2006c) , and demonstrated the unique capacity of this technology to detect antibodies in a multiplex manner with a simultaneous characterization that breaks down into their single, i. e. monoclonal, specifities (Fig. 3) .
ALLERGEN EPITOPE MAPPING
Another typical application has been the delineation of allergen reactivities as with the peanut allergens Ara h1, Ara h2 and Ara h3 by Shreffler and co-workers (Shreffler et al., 2004; Shreffler et al., 2005) . The group set up a peptide microarray immunoassay in which overlapping peptides resembled the primary sequences of the peanut allergens and analyzed the antibody response of patient and control sera. Due to the parallel epitope analysis they were able to provide evidence for considerable heterogeneity in the number and patterns of epitope recognition among individuals. Importantly, this qualitative difference in epitope diversity corre- Fig. (3) . Multiplex detection and characterization of antibodies with peptide microarrays. The fluorescence image shows a peptide microarray (four identical subarrays) displaying the entire sequence of the human thyrotropin receptor after simultaneous analysis of seven different anti-TSHR antibodies. The consensus sequence of peptides with significant antibody binding specifies the amino acid sequence of the epitope, as exemplified here for three of the seven antibodies (Andresen et al., 2006c) .
sponded to the clinical history of patients, in which those patients with greater epitope diversity had a history of significantly more severe reactions (Shreffler et al., 2004) . This kind of prognostic information was not provided by immunoassays with the recombinant antigens. The clinical significance of this peptide array approach in allergy diagnostics was further underlined by recent results of Flinterman and colleagues (Flinterman et al., 2008) . Although no specific epitopes could be attributed to the occurrence of severe reactions to peanut, the authors found again a correlation of symptoms with the number of reactive epitopes. The B-cell response in children with more severe allergic reactions to peanut was characterized by a greater diversity in their IgE epitopes directed mainly against Ara h1 and Ara h2. These results indicate that peptide array-based determination of IgE epitope binding patterns could become the principle for a prognostic test in children that identifies high-risk individuals.
MAPPING OF VIRAL EPITOPES
The delineation of the host's B cell response against viral infections has been one of the most frequent applications of traditional peptide arrays. Since the first use of the PEP-SCAN technology to map epitopes of the coat protein of foot and mouth disease virus, more than 300 papers have taken advantage of this method.
Viral nucleic acids are usually detectable earlier that antibodies. This makes detection by PCR the method of choice for most viral infections. However, for some viruses, especially those that give rise to only transient infections with either low or intermittent virus load, serology can still be more sensitive. In addition, antibody profiles are able to add considerably to PCR results. In hepatitis B virus infection, antibodies against the envelope protein can be found in patients with acute disease, while patients with chronic infections lack such antibodies. Both groups carry antibodies against the capsid protein. In addition, the antibody isotype, e. g. determination of the IgM and IgG subclass, will yield valuable information about the infections status that cannot be gained by PCR alone (Storch, 2000) .
Epitope patterns revealed by different patient subsets could potentially be informative in predicting the patient's prognosis or in gaining insight into the immune systems's battle against the infection. A perfect example on this issue was given by the Robinson group, who developed antigen microarrays to profile the breadth, strength and kinetics of epitope-specific antiviral antibody responses in vaccine trials with a simian-human immunodeficiency virus (SHIV) . 410 overlapping peptides deduced from four different SHIV antigens as well as 20 protein preparations were assembled in a SHIV proteome array and probed with sera from macaques before and after vaccination, and after challenge with a pathogenic SHIV derivative. In this way, they surveyed the evolution of anti-SHIV immune response and observed a strong convergence of antiviral B-cell specificities with a restricted set of linear epitopes in the presence of the immunogen, while vaccineinduced anti-SHIV responses against a spectrum of nonimmunodominant epitopes were lost after challenge. The array profiles rather than single antibody reactivities thereby allowed distinguishing vaccinated from challenged animals, and the breadth and persistence of antiviral antibody responses served as a predictor of mortality.
Guo et al. prepared a 4942-feature peptide array that incorporated all of the protein sequences predicted in the 15 open reading frames of the severe acute respiratory syn- Fig. (4) . General principle of the differentiated serological diagnosis with peptide arrays. Test systems based on protein antigens (left panel) are generally confined to the detection of a heterogeneous family of antibodies. The signal output reflects the quantity of bound antibodies only (Serum 1 vs. Serum 2). Substitution of the immunodominant epitopes with peptides in combination with the spatial resolution of an array platform (right panel) allows differentiating between individual antibodies within the heterogeneous group, e. g. molecules that recognize distinct regions of the antigen. By this means, peptide arrays provide the unique capacity to detect even subtle differences in antibody abundance and specificity. drome (SARS) corona virus and compared antibody reactivity patterns in acute, convalescent and deceased SARS patient sera (Guo et al., 2004) . They identified a number of peptide sequences that were uniquely recognized by sera from convalescent cases. The information about these epitopes may become important for immunization strategies, as they will most likely have contributed to neutralizing the infection. Likewise, Chow and colleagues used a peptide microarray to analyse the antigenicity of the SARS-CoV and to identify potential antigenic epitopes in the structural proteins . Particularly strong IgM and IgG antibody responses to the N-terminus of the membrane protein and the C-terminus of the nucleocapsid protein were observed that may be of future importance for the design of diagnostic tests and vaccine development.
The diagnostic surplus provided by peptide arrays due to their potential to differentiate between individual antibody specificities within a heterogeneous immune response makes them promising tools for the serological diagnosis of infectious diseases. Our group developed a 900 feature peptide microarray for the parallel and differentiated immunodiagnosis of viral infections with closely related herpes viruses and hepatitis c virus genotypes (Andresen et al., 2008) . Infections with these viruses, e. g. herpes simplex virus type 1 and 2, elicit, to a large extend, a type-common immune response with broad cross reactivity. Thus, it is not possible to serologically discriminate between these viruses with proteinbased assays. We therefore selected peptide sequences that resembled type-common as well as type-specific domains of different virus proteins. Screening of 106 characterized patient sera revealed high correlations of 90-100% in terms of sensitivity and specificity with the reference tests. Moreover, distinct antibody reactions with type-specific peptides allowed us to demonstrate the "serologic genotyping" of hepatitis c virus genotypes and subtypes as well as differentiated diagnosis of herpes virus infections (Fig. 5) .
Analysis of the antibody spectrum after immunization has shown, that the portion of B-cell receptors that recognize linear epitopes of an antigen account for less than 2% of the total antibody occurrence (Schwab et al., 1993) . However, our results and those of the other groups reviewed here demonstrate that the purposive detection of such marker antibodies from the small percentage that recognizes linear epitopes allows for a serological diagnosis that qualitatively parallels the conventional, protein-based test systems.
AUTOANTIBODY SIGNATURES IN CANCER DIAG-NOSIS?
Tumors express many antigens and there is considerable evidence that an autologous immune response to tumorassociated antigens (TAA) is developed by many patients with cancer (Boon and Old, 1997; Rosenberg 2001) . Reviewing the literature it is therefore surprising that there has been no publication of the use of peptide arrays in the profiling of autoantibodies in cancer to date. The successful implementation of related protein-based technologies, e. g. serological identification of antigens by recombinant expression cloning SEREX (Sahin et al., 1997) , may give an idea of their potential that yet has to be exploited. Zhong and colleagues, for instance, expressed cDNA of non-small cell lung cancer with a T7-phage library and screened the library with patient plasma to identify phage-expressed proteins recognized by tumor-associated autoantibodies (Zhong et al., 2006a; Zhong et al., 2006b) . With 212 initially identified candidate proteins (100-175 amino acids length) they set up a microarray-based diagnostic assay to measure multiple antibodies simultaneously. Their results show that this type of antibody profiling has excellent ability to discriminate advanced stage NSCLC from control samples (Zhong et al., 2006a) . With interest in improving early detection, the group then investigated the ability of antibody profiling to distinguish stage I lung cancer and occult disease (Zhong et al., (Andresen et al., 2008). 2006b). Starting from the same panel of 212 proteins, they identified a five-antibody marker combination that allowed for excellent discrimination between stage I non-small cell lung cancer and risk-matched control samples. This blood test was also capable of detecting occult cancer incidences up to five years before radiographic detection with high sensitivity and specificity.
With a similar approach the group of Chinnaiyan surveyed autoantibody signatures in serum samples of patients with prostate cancer and controls (Wang et al., 2005; Bradford et al., 2006) . They used repeated cycles of biopanning to select phage clones from a cancer tissue cDNA phage library in order to construct a phage-peptide microarray for serum profiling of prostate cancer patients. Using a final panel of 22 peptides, the group was able to serologically detect prostate cancer incidences with 88.2% specificity and 81.6% sensitivity, a significantly higher accuracy than obtained with a serum PSA test. Notably, the sequences in their phage display system were relatively short peptides between 11 and 134 residues, indicating the potential that arrays of synthetic peptides might have for such applications (Wang et al., 2005) .
The principal applicability of short synthetic peptides in the detection of tumor-associated autoantibodies was earlier demonstrated by Mosolits et al. (2002) . The group defined immunodominant B cell epitopes of the GA733-2 antigen, a 40 kDa glycoprotein overexpressed in the majority of colorectal carcinoma and many other carcinomas. The extracellular domain of the protein was represented by 23 synthetic peptides, each 18 amino acids in length and with six amino acids overlap between consecutive sequences. When the peptides were tested in a solid-phase ELISA against sera of patients with colorectal carcinoma, antibodies against at least one peptide were detected in 63% of the patients, compared to 13% in the control group. A particular high immunogenicity of the protein's N-terminal domain through amino acids 29 to 46 was found (50% seroreactivity in the patient group). Mintz and colleagues used a combinatorial approach with a phage random-peptide library displaying the general sequence CX 6 C to fingerprint circulating antibodies purified from the serum of prostate cancer patients (Mintz et al., 2003) . Their investigations led to the identification of the peptide motif NX(S/T)DK(S/T) which was present in a majority of seroreactive phage clones and was attributed as a mimotope of the glucose-regulated protein-78 kDa (GRP78), a heat-shock protein overexpressed in prostate cancer metastases. In further analyses, the specific reaction of the peptide with sera from prostate cancer patients was demonstrated, and, notably, the correlation of its seroreactivity with advanced stages of prostate cancer and shorter survival of the patients was shown.
CONCLUSIONS
The use of synthetic peptides as versatile probe molecules in parallel immunoassay formats is highly attractive. Firstly, well-established peptide chemistry and fully automated synthesis combined with the ease of purification and quality analysis make them an economically superior alternative to recombinant proteins. Secondly, synthetic peptides are physically and chemically much more resistant than proteins and allow fabricating comparatively robust diagnostic products. Thirdly, the serodiagnostic value benefits considerably from two key features that are unique to peptide array systems: the capacity to break down a polyclonal immune response into singular, i. e. monoclonal antibody specificities and to discriminate even subtle differences in antibody abundance and specificity.
Biomarkers are invaluable sources of modern diagnostics to early detect and estimate risks of disease manifestations, to predict outcome, progression or response to therapy. As the proteome is far more extensive than the genome, it offers a richer source of potential biomarkers (Mischak et al., 2007) . We consider the human antibodyome a particularly useful yet to a large degree unexploited source of proteinic biomarkers, since the immune system itself acts as both a strong selection filter as well as a magnifier of smallest disease associated alterations in the organism. In other words, antibodies are molecules that come readily passed through a natural screening and validation process, which makes them predestined candidates for their implementation as robust and reliable marker molecules. The potent capacity of peptide arrays to detect, differentiate and characterize antibodies in a manner that is unique to this technology imparts the appropriate diagnostic level to make the antibody accessible as a novel biomarker. It might therefore be either the presence or absence of antibodies directed against specific epitopes or rather a complex pattern of antibodies that could represent a serologic biomarker which is able to predict the severity of a disease and assist in medical decision making. Hence, the use of antibodies as diagnostic biomarkers may be one of the most promising strategies to identify patient subgroups in autoimmunity, allergy, infection and even cancer research.
